


**FIGURE 1****Solubility of m-cresol in SBECD with Varying Amounts of CJ-11,972-10**

Figure 1: Saturated meta-cresol solutions were prepared in varying amounts of SBE-CD and drug. The samples were filtered and the concentration of preservative in solution was measured. Meta-cresol concentration showed linear increase as SBE-CD was increased. The concentration of drug did not significantly alter the solubility of m-cresol in SBE-CD.

BEST AVAILABLE COPY



**FIGURE 2**

Figure 2: Compound of Formula Ia concentration vs. time at 1, 0.5, and 0.25mM compound of Formula Ia, fit to Equation 11 using Scientist software. Compound of Formula Ia was loaded to the donor side of the dialysis cell. The concentration of drug in the donor and acceptor side is presented against time. The drug reaches equilibrium in ~48 hours.

BEST AVAILABLE COPY

WO 2805082416

PCT/US2005/000100



S. Aureus log reduction presented as a function of total quantity of metacresol in the formulation

S. Aureus log reduction presented as a function of calculated non-sequestered quantity of metacresol in the formulation

Figure 3: comparison between bacterial efficacy as a function total quantity of metacresol and as a function of calculated sequestered metacresol for *S. Aureus* at 6h and 24h time points. The full circles are data corresponding to formulations containing a total of 2.95 to 3.15 mg/mL metacresol.




Figure 4: Formulation window to guaranty preservative effectiveness according to Pharm. Eur. Criteria A, no pain on injection, less than 3.5mg/mL meta-cresol, less than 80 mg/mL SBE-CD